![TRAIN Newsletter—December 2021](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
TRAIN Newsletter—December 2021
![FasterCures Quarterly Update: October 2022](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
FasterCures Quarterly Update: October 2022
![TRAIN Newsletter — September 2022](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
TRAIN Newsletter — September 2022
![Easing the Burdens of Rare Disease: Accelerating Diagnosis](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
Easing the Burdens of Rare Disease: Accelerating Diagnosis
![FasterCures Statement of Support for 21st Century Cures 2.0 Legislation](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
FasterCures Statement of Support for 21st Century Cures 2.0 Legislation
![Milken Institute Statement on the Passage of the FY2023 Omnibus Appropriations Package](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
Milken Institute Statement on the Passage of the FY2023 Omnibus Appropriations Package
![Comments on FDA’s Draft Guidance for Industry, Investigators, and Other Stakeholders on Decentralized Clinical Trials for Drugs, Biological Products, and Devices - Docket ID FDA-2022-D-2870](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
Comments on FDA’s Draft Guidance for Industry, Investigators, and Other Stakeholders on Decentralized Clinical Trials for Drugs, Biological Products, and Devices - Docket ID FDA-2022-D-2870
![Building Impactful, Transparent, and Reciprocal Relationships with Industry Partners](/sites/default/files/oembed_thumbnails/iOy7oW-GkuAq0bXRT4u9u5LM72b9Z2d2IPN59ht1uUI.jpg)
Building Impactful, Transparent, and Reciprocal Relationships with Industry Partners
![FasterCures Quarterly Update—April 2024](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)
FasterCures Quarterly Update—April 2024
![TRAIN Newsletter — April 2024](/themes/custom/milken_emulsify/images/default-search-thumbnail.png)